NDAC/antiviral committee meeting
This article was originally published in The Tan Sheet
Tentatively scheduled for Jan. 12-13. FDA has not announced the topics for the meeting. However, reconsideration of the Rx-to-OTC switch of Burroughs Wellcome's Zovirax (acyclovir) in the treatment of genital herpes is awaiting consideration by the joint committee. The committee postponed a decision on the switch in July to allow Burroughs Wellcome time to submit data that addressed issues raised at an FDA public hearing on May 19 ("The Tan Sheet" July 4, p. 1). Other tentative 1995 meeting dates for NDAC include March 27-28; July 13-14; Sept. 28-29 and Nov. 16-17
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC